The Regulation of Follow-on Biologics

by Latham & Watkins LLP
Contact

John Manthei is a partner at Latham & Watkins and serves as global Co-chair and Washington, D.C. Chair of the firm's Health Care and Life Sciences Practice. His practice focuses on regulatory matters involving the US Food and Drug Administration (FDA) for the medical device, pharmaceutical, biotechnology, food and dietary supplement industries.

What is new in the world of follow-on biologics?

Manthei: Congress enacted the Biologics Price Competition and Innovation Act of 2009 to provide an alternative to the submission of a Biologics License Application for certain biologic drugs that are interchangeable with or similar to previously licensed biologic products. The Act expanded the FDA's authority to regulate follow-on biological products pursuant to this new regulatory scheme. 

What changes have there been in the regulation of these products?

Manthei: FDA’s implementation of the regulatory scheme for follow-on biologics continues to take shape. In the past year, FDA has taken steps to interpret and implement these new provision. The past year has also seen developments in the responses of state governments and other stakeholders. The implementation of this new legislation is important for both innovators of licensed biologics drugs and sponsors of follow-on biologics. Biologics companies should understand and consider the impact of the evolving follow-on biologics program on their respective businesses.

What does the Biologics Price Competition and Innovation Act entail?

Manthei: The Biologics Price Competition and Innovation Act establishes two product categories for follow-on biologics – biosimilars and interchangeable biologics.  It includes provisions regarding data requirements, the product development and licensure process, patents and exclusivity, among other things. In addition, the Biosimilars User Fee Act of 2012 establishes user fees associated with the development and approval of follow-on biologics, including various development fees that apply early in the regulatory process. At the same time, the legislation leaves open a number of major issues that FDA must address. These include issues relating to product nomenclature, standards for interchangeability, and the burdens of the data requirements under the new regulatory scheme. 

As a result, these and other important issues must be resolved by FDA’s implementation of the Act.  In addition to the federal legislation, there have also been recent state legislative efforts dealing with the substitution of follow-on biologics for brand-name products by pharmacies, as well as developments in the European Union which may ultimately impact US regulation.   

What are the three main takeaways that I should know about this new regulatory scheme?

1. Although the provisions of the Act may provide new incentives for the development of follow-on biologics, FDA’s implementation of the follow-on biologic program remains ongoing and full implementation is likely to take several years. As of June 2013, it does not appear that FDA has received a single application for a follow-on biologic product although it has held preliminary meetings with several companies.

2. FDA has issued numerous draft guidances and provided various opportunities for public and industry input as it implements the new regulatory scheme. Interested parties should be sure to stay abreast of FDA’s activities and take advantage of opportunities to provide input on issues important to their business. 

3. The licensure pathway created by the Biologics Price Competition and Innovation Act differs from the follow-on biologic legislation in place in the EU, which approved its first follow-on biologic in 2006.  In particular, the Act allows FDA to license follow-on biologics as either biosimilar or interchangeable, and offers the benefits of exclusivity to certain interchangeable biologics.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Latham & Watkins LLP | Attorney Advertising

Written by:

Latham & Watkins LLP
Contact
more
less

Latham & Watkins LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.